zurück

Emicizumab (new indication: moderate hemophilia A; without factor VIII inhibitors; severe bleeding phenotype)

 

Subject:

  • Active Substance: Emicizumab
  • Name: Hemlibra®
  • Therapeutic area: Hemophilia A
  • Pharmaceutical company: Roche Pharma AG

 

Time table:

  • Start: 01.03.2023
  • Publication of assessment: 01.06.2023
  • End of public hearing: 22.06.2023
  • Final decision by G-BA: mddle of August 2023

 

Comparative therapy:

  • Plasmatic or recombinant blood coagulation factor VIII preparations, used as routine prophylaxis